



## Clolar<sup>®</sup> (clofarabine) – First-time generic

- On May 10, 2017, Fresenius Kabi launched Abon's [AP-rated](#) generic version of Genzyme's [Clolar \(clofarabine\)](#) injection.
  - Abon is eligible for 180 days of market exclusivity.
- Clolar is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.
  - This indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with Clolar.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.